Bayer Aktiengesellschaft

Farbenfabriken Bayer Aktiengesellschaft

Walter Puls

Lutz Muller

Delf Schmidt

Hilmar Bischoff

Werner Frommer

Bodo Junge

Siegfried Goldmann

Dieter Petzinna

Klaus Schlossmann

Rudiger Sitt

Hans P Krause

Joachim Bender

Jurgen Stoltefuss

Fred R Heiker

Friedrich Bossert

Gunther Kinast

Hans-Peter Krause

Dietmar Schafer

Uwe Keup

Elisabeth Perzborn

Ulrich Rosentreter

Klaus Schaller

Friedel Seuter

Horst Boshagen

Gunter Thomas

Joachim Ippen

Hans J Ahr

Horst Gericke

Otto Wagner

Delt Schmidt

Ulrich Heber

Hans-Jurgen Ahr

Novel blood sugar-lowering dihydropyridinelactones of the formula ##STR1## in which R represents halogen, C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.10 -alkylthio, C.sub.1 -C.sub.10 -alkylsulphinyl, C.sub.1 -C.sub.10 -alkylsulphonyl, cyano, C.sub.1 -C.sub.6 - mono- or polyfluoroalkyl, C.sub.1 -C.sub.6 -mono- or polyfluoroalkoxy or nitro,

Novel 1-alkyl-substituted 1,4-dihydropyridinelactone anti-diabetics

Blood sugar levels are reduced by administration of novel 4-thienyl-dihydropyridines of the formula ##STR1## in which R.sup.1 represents 1 or 2 halogen atoms, or represents straight-chain, branched or cyclic alkyl with up to 8 carbon atoms,

Lowering blood sugar with novel 4-thienyl-dihydropyridines

Certain 4-thienyl-dihydropyridines

Blood-sugar-lowering dihydropyridines of the formula ##STR1## in which R.sup.1 represents phenyl, naphthyl, thienyl, pyridyl, chromenyl or thiochromenyl, it being possible for the radicals mentioned each to carry up to 2 identical or different substituents from the series comprising halogen, alkyl, alkoxy and alkylthio with in each case up to 6 carbon atoms, fluoroalkyl and fluoroalkoxy with in each case up to 3 carbon atoms and 3 fluorine atoms, nitro and cyano,

Dihydropyridine compounds and their use in reducing blood sugar

Reducing blood sugar with the novel dihydropyridinelactols, or salts thereof, of the formula ##STR1## in which R.sup.1 represents a phenyl, naphthyl, thienyl, pyridyl, chromonyl, thiochromonyl or thiochromenyl radical, the stated radicals optionally containing 1 or 2 identical or different substituents from the group consisting of fluorine, chlorine and bromine, alkyl, alkoxy and alkylthio, each having 1 to 6 carbon atoms, and fluoroalkyl or fluoroalkoxy, each having up to 3 carbon atoms and 3 fluorine atoms, and nitro and cyano,

Dihydropyridinelactols and their use as medicaments which influence

The invention includes certain 3,4,5-trihydroxypiperidine compounds, methods for their preparation, compositions containing said 3,4,5-trihydroxypiperidine compounds and methods for the use of said compounds and compositions. The subject matter of the invention is useful against diabetes, hyperlipaemia and adiposity as well as in animal nutrition.

Antidiabetic 3,4,5-trihydroxypiperidines

The invention relates to amino-cyclitol derivatives of Formula (I) and their individual anomers. Also included in the invention are processes for the manufacture of said amino-cyclitol derivatives and their individual anomers, compositions containing said amino-cyclitol derivatives or anomers; and methods for the use of said derivatives and anomers for the treatment of diabetes, adiposity or hyperlipaemia.

Medicaments containing amino-cyclitol derivatives

The invention relates to animo-cyclitol derivatives of Formula (I) and their individual anomers. Also included in the invention are processes for the manufacture of said amino-cyclitol derivatives and their individual anomers, compositions containing said amino-cyclitol derivatives or anomers; and methods for the use of said derivatives and anomers for the treatment of diabetes, adiposity or hyperlipaemia.

The invention relates to guanidinothiazol derivatives of Formula (I) as defined herein, said compounds being useful for influencing lipid metabolism, as antithombotic agents and as antimycotic agents. Also included in the invention are compositions containing said guanidinothiazol derivatives of Formula (I) and the use of said compounds and compositions for treatment of the above-mentioned conditions. In addition, the invention includes methods for the manufacture of the guanidinothiazole derivatives of Formula (I).

Guanidinothiazole derivatives containing alkylene bridges, and their use

Amino-cyclitol derivatives and medicaments containing them

The invention relates to 4-,5-and 6-substituted 2-amino pyridines of Formula (I) and methods for their preparation. Also included in the invention are compositions containing said 2-amino pyridines of Formula (I) and the use of said compounds and compositions for use inter alia, as lipid absorption inhibitors.

Substituted 2-amino-pyridine derivative compounds, their production and

The invention relates, inter alia, to 3,4,5-trihydroxypiperidine compounds of Formula (I), infra, to methods for the manufacture of said compounds, to pharmaceutical compositions containing said compounds and to methods for the use of said compounds and compositions. Also included in the invention are concentrates, premixes and feedstuffs containing said compounds.

3,4,5-Trihydroxypiperidine compounds and their use as medicaments and in

The invention relates to .alpha.-hydroxyalkyl-3,4,5-trihydroxypiperidines defined by Formula (I), infra, and pharmaceutical compositions and medicaments containing said compounds. Also included in the invention are methods for the use of said compounds, compositions and medicaments as inhibitors of .alpha.-glucoside hydrolases; and intermediates for the compounds of said Formula (I).

2-Hydroxyalkyl-3,4,5-trihydroxy-piperidine compounds, their production

The invention relates to 1-alka-2,4-dienyl-2-hydroxymethyl-3,4,5-trihydroxypiperidine compounds which are, inter alia, potent inhibitors for .alpha.- glucoside hydrolases and effect lipid absorption. Also included in the invention are methods for the manufacture of the said compounds, compositions containing said compounds and methods for the use of said compounds and compositions.

1-Alka-2,4-dienyl-2-hydroxymethyl-3,4,5-trihydroxypiperidines as

According to the present invention inhibitors for glycoside hydrolases, and in particular glucosidase inhibitors especially saccharase inhibitors, which are active in the digestive tract are formed by culturing organisms of the family Bacillaceae, particularly by strains of the genus Bacillus. It has also been found that certain strains of organisms of the family Bacillaceae, especially strains DSM 7, DSM 704 and DSM 675 produce the antibiotic known as 1-desoxynojirimycin. The invention therefore provides a method of producing 1-desoxynojirimycin which comprises culturing a 1-desoxynojirimycin producing organism of the genus Bacillus. Inhibitors for glycoside hydrolases and the invention includes methods for producing such inhibitors, pharmaceutical compositions containing the inhibitors and methods of treatment involving the use of the inhibitors.

Growing community of inventors

Wuppertal, Germany

Walter Puls